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Glioblastoma multiforme, the most frequent type of primary brain tumor, is a rapidly evolving and spa-
tially heterogeneous high-grade astrocytoma that presents areas of necrosis, hypercellularity and mi-
crovascular hyperplasia. The aberrant vasculature leads to hypoxic areas and results in an increase of
the oxidative stress selecting for more invasive tumor cell phenotypes. In our study we assay in silico
different therapeutic approaches which combine antithrombotics, antioxidants and standard radiotherapy.
To do so, we have developed a biocomputational model of glioblastoma multiforme that incorporates the
spatio-temporal interplay among two glioma cell phenotypes corresponding to oxygenated and hypoxic
cells, a necrotic core and the local vasculature whose response evolves with tumor progression. Our nu-
merical simulations predict that suitable combinations of antithrombotics and antioxidants may diminish,
in a synergetic way, oxidative stress and the subsequent hypoxic response. This novel therapeutical strat-
egy, with potentially low or no toxicity, might reduce tumor invasion and further sensitize glioblastoma
multiforme to conventional radiotherapy or other cytotoxic agents, hopefully increasing median patient
overall survival time.
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1. Introduction
Glioblastoma Multiforme (GBM), a World Health Organization (WHO) grade IV astrocytic glioma, is
the most aggressive and frequent primary brain tumor (Louis et al., 2007). GBM may develop (span-
ning from 1 year to more than 10 years) from lower-grade astrocytomas (WHO grade II) or anaplastic
astrocytomas (WHO grade III), but more frequently, it manifests de novo. The median overall survival
ranges from 12 to 15 months after diagnosis despite using the current standard care. It includes maxi-
mal safe resection followed by radiotherapy in combination with the chemoterapeutic (alkylating) agent
temozolomide (Van Meir et al., 2010). After treatment, relapse occurs typically within a few months
due to the GBM radio and chemoresistance and its remarkable infiltrative nature.
At the tissue level, the presence of necrosis and microvascular hyperplasia is characteristic of GBM,
in contrast to lower-grade gliomas where peritumoral vascular damage is infrequent or absent. Histolog-
ical samples of GBM frequently show thrombosed vessels within necrotic cores. Tumor cells actively
migrate away from oxygen-deficient (hypoxic) regions, originated after vascular injury. They form hy-
percellular regions that surround the necrotic cores (Rong et al., 2006).
At the molecular level, adaptation of tumor cell subpopulations to strong spatio-temporal variations
of oxygen availability is mediated by the hypoxia-inducible factor (HIF-1). This complex activates the
transcription of hundreds of genes that play key roles, among others, in cell death avoidance, genetic in-
stability, vascularization, glucose metabolism, pH regulation, immune evasion and invasion (Kelly et al.,
2008; Semenza, 2012). Under acute hypoxia, tumor cells will tend to cease or reduce their prolifera-
tion rate as a means to decrease oxygen consumption. This mechanism relies primarily on the subunit
HIF-1α of the heterodimer HIF-1, which arrests DNA replication in the presence of oxygen stress
(Hubbi et al., 2013). Moreover, the levels of free radicals increase during cycles of hypoxia and there is
evidence that they are also molecular switches influencing the stabilization of HIF-1α (Wilson and Hay,
2011).
In contrast to normal cells, the survival of GBM cells is favored by an increase in free radicals since
the oxidative stress forces the cells to produce antioxidant enzymes such as catalase and superoxide dis-
mutase to control the exacerbated level of free radicals (Kovacic and Osuna, 2001; Schumacker, 2006).
The increase in these antioxidant enzymes strongly interferes with the action of radio/chemotherapy,
that kill tumor cells by inducing an increase in free radicals (Tennant et al., 2010). In addition, free radi-
cals inactivate the tumor suppressor protein p53, enabling tumor cells to escape apoptosis (Cobbs et al.,
2003). Thus, disrupting this signaling process in tumors, may be expected to promote hypoxia-induced
death (Joiner et al., 2009) and to restore redox homeostasis, turning off the hypoxic response.
Many evidences indicate that the invasive ability of GBM and its resistance to chemo and radiother-
apy is mostly due to phenotypic changes that are intimately linked to the presence of hypoxia, initiated
by oxygen deprivation after a vaso-occlusion event. Under these conditions, the levels of HIF-1α in-
crease driving the expression of many pro-angiogenic factors such as the Vascular Endothelial Growth
Factor (VEGF). The accumulation of VEGF promotes an aberrant neovascularization (Semenza, 2009)
composed of a high density of non functional microvessels which are leaky and devoid of pericytes.
This structure allows the contact between blood and tumor cells and initiates the coagulation cascade
and the formation of thrombi, a major cause of patient death (Jenkins et al., 2010; Young et al., 2012).
Furthermore, the transmembrane protein tissue factor (TF) not only activates the extrinsic pro-coagulant
pathway but also contributes to GBM cell invasion and neovascularization (Harter et al., 2013). In gen-
eral, thromboembolism, i.e. vaso-occlusion events of large vessels, is recognized as a major complica-
tion of cancer and a common cause of death in cancer patients. There is strong evidence linking venous
thromboembolism (VTE) and malignancy (Khorana and Francis, 2008; Green and Kwaan, 2009).
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Thromboembolic complications include a broad spectrum of clinical problems, a fact that has lead to
the use of different ways of thromboprophylaxis (Khorana and Francis, 2008; Green and Kwaan, 2009)
for cancer patients. Bastida et al. (1984) proved that glioma cell lines secrete pro-thrombotic factors,
and in fact, glioma patients have a high incidence of VTE, with several studies suggesting that 25%-30%
of these patients suffer thromboembolic events (Streiff et al., 2004; Simanek et al., 2007).
It is also known that the more tumoral tissue is removed during surgery of high-grade gliomas the
less-likely are the patients to die from VTE (Brose and Lee, 2008; Simanek et al., 2007). Thus, all
this body of evidence has led to the consideration of thromboprophylaxis using anticoagulants, such
as for instance low molecular weight heparine (LMWH), for glioma patients, specially in those with a
high potential risk of developing VTE (Hamilton et al., 1994; Batchelor and Byrne, 2006; Jenkins et al.,
2010; Khorana and Francis, 2008).
In addition to their potential use to diminish the risk of VTE, LMWH exerts a direct effect on tumor
cells and tumor stroma, as it can directly kill cancer cells and also inhibit the neovascularization pro-
cess, which downregulates cell invasion (Santos et al., 2010; Svensson et al., 2011; Green and Kwaan,
2009). In this context, there have been a limited number of small-scale clinical studies evaluating the
safety of antithrombotic therapy in GBM patients with a VTE risk supporting the safety of the approach
(Schneider et al., 2010). However, no extra benefits beyond the substantial reduction in the VTE risk
have been proven yet.
In our previous study (Martı´nez-Gonza´lez et al., 2012), we developed a minimal mathematical model
of GBM progression incorporating the evolution of different tumor cell subpopulations and chemicals
in the tumor microenvironment. The implications of that work are that antithrombotics would have a
restrain effect on tumor progression, thus allowing a better local control of the tumor. However the
potential gain achieved by the use of antithrombotics alone is modest. In this paper we will discuss a
way to potentially obtain a much more substantial tumor control by targetting simultaneously the vessel
occlusion events and the accumulation of hypoxia inducible factors.
Thus, in this paper we study in silico a more elaborated system, including two different cell phe-
notypes, the oxygen concentration in the brain tissue and a dynamic vasculature to assess the potential
effect of combined therapies targeting simultaneously the vessel-occlusion events and the “normaliza-
tion” therapy (antioxidation) together with standard radiotherapy as an example of cytotoxic therapy.
Our conceptual framework is summarized in Fig. 1. Vascular regularizing therapies and antioxidants
follow different pathways aimed at reducing tumor hypoxia by means of directly impacting on HIF-1α
levels. This effect would decrease oxidative stress and the subsequent hypoxic response. To achieve
this goal, antioxidants act on the oxidation balance whereas antithrombotics reduce vaso-occlusions and
hypoxic areas. The overall effect is an increment in oxygenation. Both therapies should ameliorate
vessel functionality by reducing pro-thrombotic and angiogenic factors. In addition, the higher oxy-
gen levels and decreased oxidative stress may provide the extra benefit of a sensitization to radio and
chemotherapy, that might result in a synergistic response to the treatment.
Our plan in this paper is as follows. First, in Sec. 2 we present the basic model equations describing
tumor progression in detail and discuss the assumptions behind them. Next, in Sec. 3 we discuss how
to incorporate the different therapies into the model. Parameter estimation is addressed in Sec. 4. Once
the model is set up and realistic parameter ranges identified we move on to studying the dynamics; the
main results being outlined in Sec. 5. Finally, in Sec. 6 we discuss the implications of our findings and
summarize our conclusions.
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FIG. 1. Schematic description of how a combined treatment of antithrombotics and antioxidants may slow down GBM
invasion and sensitize the tumor to radio and chemotherapy.
2. Mathematical model of tumor progression
In our work, we propose a mathematical model that incorporates the spatio-temporal interplay among
two tumor cell phenotypes corresponding to well oxygenated and hypoxic cells, a necrotic core, the
oxygen distribution and a dynamic vasculature.
2.1 Cell phenotypes
The so-called migration/proliferation dichotomy in tumor cells refers to the commonly assumed fact
that cancer cells do not move and proliferate simultaneously (Giese et al., 2003). The switch between
a more proliferative and a more invasive phenotype cannot be only mutation driven (Hatzikirou et al.,
2010; Onishi et al., 2011) and in fact it has been suggested that invasive glioma cells are able to revert
to a proliferative cellular program and vice versa, depending on the environmental stimuli (Giese et al.,
2003; Keunen et al., 2011). Specifically, several studies have linked hypoxia to the invasive behavior of
different types of tumors and their relationship with metastasis and negative prognosis (Bristow and Hill,
2008; Kalliomaki et al., 2009; Elstner et al., 2007).
Following these biological facts we will assume in our model that the heterogeneous oxygen dis-
tribution is the driving force that triggers phenotypic changes of tumor cells as shown schematically
in Fig. 2. Thus, the local oxygen concentration will be considered to have a major influence on the
cell phenotype expression. It will be assumed to induce spatio-temporal variations of phenotypic ex-
pressions via the HIF-1α activation/deactivation pathways. Therefore, will focus ourselves only on two
dominant tumor cell phenotypes. A first phenotype with a spatio-temporal density described by a non-
negative function Cn(x, t) :R2 →R+0 corresponds to more proliferative tumor cells. A second phenotype
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FIG. 2. Oxygen pressure influences the phenotype of a tumor cell. Depending on the oxygen pressures various switching
mechanisms arise coupling the populations: Normoxic to hypoxic Snh for oxigen concentrations O
(S)
2 with characteristic time
τnh; hypoxic to normoxic Shn above O(S)2 with characteristic time τhn and hypoxic to necrotic Shd for pressures below O
(D)
2
with characteristic time τhd . High oxygen pressures favor the existence of less mobile phenotypes with shorter doubling times
τn . On the contrary, cells respond to low oxygen pressures by expressing more motile phenotypes with larger doubling times
τh .(Brat et al., 2004).
will be described by (a nonnegative) function Ch(x, t) : R2 → R+0 accounting for tumor cells which are
more mobile and resistant to therapies. Both phenotypes have described to have a major role in GBM
progression (DeBerardinis et al., 2007; Giese et al., 2003; Keunen et al., 2011; Onishi et al., 2011). For
convenience, we will refer to them somewhat imprecisely as “normoxic” and “hypoxic” phenotypes
since they correspond to the limit behavior of the tumor cell density after either very long oxygenation
periods (Cn(x, t)) or persistent oxygen deprivation periods (Ch(x, t)).
The equations governing the interplay between the dominant phenotypes are
∂Cn
∂ t = Dn∇
2Cn +
Cn
τn
(
1−Cn +Ch +Cd
C(M)
)
+
Shn
τhn
Ch−
Snh
τnh
Cn, (2.1a)
∂Ch
∂ t = Dh∇
2Ch +
Ch
τh
(
1−Cn +Ch +Cd
C(M)
)
−
Shn
τhn
Ch +
Snh
τnh
Cn−
Shd
τhd
Ch. (2.1b)
The first right-hand-side terms in Eqs. (2.1a) and (2.1b) account for cellular motility. Since the hy-
poxic phenotype is more migratory than the normoxic one (Berens and Giese, 1999; Giese et al., 2003;
Bristow and Hill, 2008; Gorin et al., 2004), the hypoxic cell diffusion coefficient Dh should be chosen
to be larger than the normoxic one Dn. This is a key assumption of our model whose implications will
be elucidated in detail.
The second terms in Eqs. (2.1a) and (2.1b) are classical logistic growth terms for the tumor cell
populations with proliferation times τn and τh, respectively, and a maximum cell density CM that the
brain tissue can accommodate. The migration-proliferation dichotomy suggests that τn < τh; this is
also supported by the observation that hypoxic cells reduce their proliferation rate by arresting DNA
replication (Hubbi et al., 2013). Since growth is assumed to be space-limited we incorporate also the
necrotic tissue density Cd(x, t) into the saturation terms (see below).
The third and fourth terms in Eqs. (2.1a) and (2.1b) represent the phenotypic switch under different
oxygenations. The switch functions Snh, Shn depend on the oxygen pressure. Under low oxygen con-
ditions (O(S)2 < 7 mmHg), normoxic cells change their phenotype to the hypoxic one, whereas above
O(S)2 hypoxic cells recover their oxic phenotype. τnh and τhn denote the characteristic switching times
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of these processes. Usually τnh is much shorter than τhn since cells incorporate mechanisms to respond
almost instantaneously to the absence of oxygen. However the reverse process is not so fast, specially
in cells that have already suffered several oxygen deprivation episodes (Hsieh, 2010).
To close the model we have to incorporate an equation for the necrotic tissue density Cd(x, t)
∂Cd
∂ t =
Shd
τhd
Ch. (2.1c)
Hypoxic cells (2.1b) feed the necrotic tissue in Eq. (2.1c) under persistent anoxic (O(D)2 < 0.7 mmHg)
conditions. This is accounted for by the switch function Shd and a rate 1/τhd . The explicit form of the
switch functions will be taken to be (Martı´nez-Gonza´lez et al., 2012)
Snh(O2) =
1
2
[
1− tanh
(
O2−O
(S)
2
∆O2
)]
, (2.2a)
Shn(O2) =
1
2
[
1+ tanh
(
O2−O
(S)
2
∆O2
)]
, (2.2b)
Shd(O2) =
1
2
[
1− tanh
(
O2−O
(D)
2
∆O2
)]
(2.2c)
were the three step-like switch functions Snh, Shn and Shd ∈ [0,1] and the parameter ∆O2 described the
characteristic range of oxygen variations where the transitions occur.
2.2 Modelling oxygen distribution through the tissue
To simplify the analysis, yet retaining the basic interplay of the key underlying biological processes
in GBM, we will stick to a one dimensional geometry with the oxygen flow coming from a network
(1D lattice) of vessels. In the brain, spatio-temporal inhomogeneities arise in the parameter values (e.g.
different propagation speeds in white and gray matter which also vary in time as the tumor progresses)
and anisotropies (e.g. on the diffusion tensor with preferential propagation directions along white matter
tracts (Painter and Hillen, 2013)). However, those complexities would add on top of the phenomena to
be described in this paper. Thus, in what follows, we will focus our study on a representative spatial
section which will provide key spatial and time metrics enabling us to incorporate, at a later stage, the
action of various therapeutic modalities.
The spatio-temporal evolution of oxygen O2(x, t) is similar to the one chosen in Martı´nez-Gonza´lez et al.
(2012), although now oxygen sources are located on the blood vessels, and is governed by
∂O2
∂ t = DO2∇
2O2−
αnCn +αhCh
O(T )2 +O2
O2 + JχC(χFOvi2 −O2). (2.3)
The first term in the right-hand-side of Eq. (2.3), accounts for oxygen diffusion in the brain tissue
and assumes an homogenous and isotropic diffusion coefficient DO2 . The second term models the
oxygen consumption by both normoxic and hypoxic cells at rates αn and αh, respectively. The saturation
Michaelis-Menten constant O(T )2 corresponds to the oxygen pressure level at which the reaction rate is
halved. The third term describes the oxygen flow from the vessels to the tissue. The oxygen pressure
in the ith blood vessel will be denoted as Ovi2 (t). The multiplicative function J(x) in Eq. (2.3) accounts
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for the spatial distribution of the oxygen supply and depends on the blood vessels positions pi and their
sizes vi. Here, J will be taken to be a combination of Gaussian functions of the form
J(x) = JO2
N
∑
i=1
e−(x−pi)
2/v2i , (2.4)
with JO2 = 10−6 s−1 as the estimation for the oxygen exchange coefficient which is considered to be
constant in time and the same for all of the vessels. The positions pi of the vessels will be considered
to be equidistant, with separations of 300 µm. The vessel widths vi (being capillaries), will be taken to
be 30 µm in diameter. Since oxygen diffuses along and through the vasculature it is reasonable to think
that vessels of similar size will have similar nutrient concentrations. Therefore, Ovi2 is considered to be
constant along time for all i. Furthermore, χC and χF in Eq. (2.3) are factors accounting for the chronic
and fluctuating hypoxia induced by the tumor and will be explained in depth in Section 2.3.
Oxygen diffuses successively through the intracellular fluid, cell membranes and cytoplasm which
have abrupt spatial variations. However, previous works (Pogue et al., 2001; Dac¸u et al., 2003; Powathil et al.,
2012) have proved that using an average diffusion coefficient for oxygen as in Ec. (2.3) provides a good
approximation to the diffusion process.
Given that mean oxygen pressure in arterial blood is around 95 mmHg (Kimura et al., 1996) and
venous values are around 30-40 mmHg, we will employ for the oxygen pressure within the capillaries a
constant value Ovi2 = 80 mmHg.
2.3 Vasculature and coagulation
The sources of nutrients and oxygen in the brain are the blood vessels (capillaries in here). We will also
assume that oxygen concentration in the capillary network does not follow the variations induced by the
cardiac pumping in the major blood vessels (Dac¸u et al., 2003), because of the fast time scale of those
variations.
Thrombi formation leading to the developing of pseudopalisading structures (Brat et al., 2004; Rong et al.,
2006) may be in part connected with the vascular remodeling induced by tumor cells. The pro-angiogenic
stimuli give rise to hyperplasia in the endothelial cells which lose cell to cell unions causing vascular
permeability and a malfunctioning of the blood-brain barrier (BBB). The generated orifices allow the
blood to be in contact with the tumor cells. It results in plasma coagulation factors in direct connection
with the tumor tissue. As a consequence, fibrin coagulates and platelets aggregate. The tumor secrets
TF that activate the so-called extrinsic coagulation pathway what provides an additional source for the
strong pro-thrombotic activity of GBM (Ruf et al., 2010).
We will consider that vessel functionality decreases as tumor cell density increases. Once cells
accumulate around the vessels the constitutive expression of TF by cancer cells will trigger local and
systemic activation of the coagulation cascade as described above.
In our approach, blood vessels will be first assumed to become semifunctional when the tumor cell
density is above a certain threshold C(F) implying the onset of fluctuating hypoxia. The step-like switch
function χF reproduces this phenomena depending on a cellular density C(F) and a random dynamic
noise z (0 < z < 1) given by the equation
χF(Cn +Ch +Cd , t∗) = 1− z
1
2
[
1+ tanh
(
(Cn +Ch +Cd)−C(F)
∆c
)]
. (2.5a)
We will also assume that when the tumor cell density around the vessel grows beyond a higher threshold
value C(C), the coagulation process is irreversible and chronic hypoxia sets in due to the complete lack
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of oxygen flow. This process is modelled by a step-like switch function χC given by
χC(Cn +Ch +Cd, t∗) = min
{
1
2
[
1− tanh
(
(Cn +Ch +Cd)−C(C)
∆c
)]
: t 6 t∗
}
. (2.5b)
Finally, the vasculature sensitivity threshold ∆c is estimated to be around 0.02 C(M) cells.
3. Modelling therapies
3.1 Antithrombotic therapy
We will assume that low molecular weigh heparine (LMWH) decreases the expression of TF and in-
creases the vascular functionality. Thus, it prevents the formation of coagulates. This therapy will be
modelled by increasing the thresholds at which the vessels become unstable from C(F) = 0.5C(M) to
C(F) = 0.6 - 0.8 C(M) and from C(C) = 0.7C(M) to C(C) = 0.8− 0.99C(M). Although the precise values
are not known and probably depend on a number of additional features, they will allow us to simulate
the proof-of-principle of the antithrombotic therapy.
In addition to the prevention of VTE there are other several direct mechanisms of action of LMWH
on tumor cells: direct cell killing (Santos et al., 2010), antiangiogenic effects (Svensson et al., 2011) and
many others (see e.g. Green and Kwaan, 2009, Chap. 15). Since those effects are difficult to quantify
we will assume in this paper that the net effect of the antithrombotic therapy is to increase the vessel
functionality thresholds C(C) and C(F).
In this paper we will assume that drug administration leads to a blood concentration level that is
sufficient to induce the required effect and as such we will not include the details of the pharmaco-
kinetics of the drugs. The same applied to the treatment to be described in Sec. 3.2.
3.2 HIF-1α stabilization treatment
When oxygen is present, HIF-1α is continuously synthesized by the cell, but it is unstable and degraded
with a half-life of about 2-3 minutes. However, as a consequence of the cycles of hypoxia due to the
anomalous vasculature, free radicals are originated regulating and stabilizing the expression of HIF-1α
even when vascular functionality is restored. In fact, U87 glioma cell line shows higher HIF-1α expres-
sion under cyclic than under chronic hypoxia (Hsieh, 2010). It is believed that the sequence of oxygen
deprivation episodes may drive the accumulation of HIF-1α in the cell nucleus. Therefore, cells need
longer times to return to the normoxic phenotype state (Semenza, 2009). This HIF-1α stabilization sig-
nificantly increases invasiveness and secretion of angiogenic factors and drives the intrinsic and extrinsic
coagulation routes.
Free radicals are usually detoxified by a complex system of proteins and antioxidant macromolecules
which maintain the cell redox homeostasis. Antioxidative-based treatments, such as those with cauler-
pine or tempol, result in a HIF-1α inhibition and consequently in an antiproliferative effect in GBM
murine xenograft models (Hsieh, 2010). Thus, antioxidative-based adjuvant therapies would provide
faster ways for cells to revert to their normoxic state under oxic conditions. They decrease the HIF-1α
accumulation and enable the recovery of the redox homeostasis. In our model, we will include the effect
of the antioxidative therapy by decreasing the time of recovery of the normoxic phenotype τhn from 96
h to a smaller value in the range 8-48 h.
It is worth mentioning that based on the go or grow hypothesis, the diffusion coefficient of hypoxic
cells is larger than for the normoxic cells, however, it is not known whether targeting HIF-1α via an-
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tioxidative therapy would induce a significant change in them. Consequently, these parameters have a
10% variability in each simulation and are constant in time along the treatments.
3.3 Radiotherapy
The standard radiotherapy protocol for high grade gliomas consists of a total of 60 Gy in fractions of 2
Gy given in 30 sessions from monday to friday leading to a treatment duration of 6 weeks. Treatment is
usually started several (2-4) weeks after surgery.
To describe the effect of the therapy in our model, cell death induced by radiation is included in
the simulations instantaneously once per day (monday to friday) during 6 weeks. We have chosen the
simulations start 2 weeks after surgery, thus radiotherapy starts at week 2.
In the absence of oxygen, the unstable free radicals generated by radiation have a longer half life.
Then, they can react with H+ restoring its chemically original form without the need for biological
and enzymatic intervention. The overall result is that better oxygenated cells are more radiosensitive
(Joiner et al., 2009). Thus we will assume the effect of radiotherapy to depend on the local oxygen
concentration O2(x, t) at the time of the therapy. Denoting by RTox the cell surviving fraction under
oxic conditions and RThyp the surviving fraction under hypoxic conditions, we will employ for the total
surviving fraction under a local oxygen pressure O2(x, t), the equation
S(x, t) = RTox
O2(x, t)
Ovi2
+RThyp
(
1− O2(x, t)
Ovi2
)
. (3.1)
4. Parameter estimation and computational details
4.1 Parameter estimation
We resort to available experimental values from human glioma models to obtain order-of-magnitude es-
timates of the intervening parameters in our equations. Typical values of the used biological parameters
are shown in Table. 1 (see also further parameters details in Martı´nez-Gonza´lez et al. (2012)).
First, the maximum cell density C(M) has been estimated in previous works (see e.g. Rockne et al.,
2010) to be about 106 cell/cm2. Oxygen pressure threshold for hypoxic metabolism O(S)2 is cell line
dependent but experimental evidence supports for glioma the choice of 7 mm Hg (Vaupel, 2004). The
Michaelis-Menten constant, O(T )2 has to be smaller than this parameter yet larger than anoxia threshold,
O(D)2 , about 0.7 mm Hg (Brown et al., 2004). We have chosen it to be 2.5 mm Hg (Dac¸u et al., 2003).
The oxygen diffusion coefficient DO2 is classically known to be around 10−5 cm2/s (Dac¸u et al., 2003)
while the cell diffusion coefficients are not so readily accessible in vivo.
The hypoxic diffusion coefficient has been considered to be around the mean data reported in
Rockne et al. (2010) and ten times larger than the normoxic one. In addition, for high-grade glioma, the
largest radial velocity v (≈3 cm/y) can be related to the hypoxic cell propagation whereas the smallest
radial velocity (≈1 cm/y) can be related to the normoxic one. For instance, considering the Fisher-
Kolmogorov approximation to the radial cell propagation (v ≈ 2
√
D/τ), the normoxic and hypoxic
doubling times τ (14 and 24 days respectively) can be extrapolated, which are also similar to those used
in Rockne et al. (2010). The normoxic oxygen uptake was obtained from a healthy tissue of 0.2C(M)
as cell density with oxygen consumption of 15 mmHg/s (Dac¸u et al., 2003). Hypoxic oxygen uptake
is several times smaller than the normoxic one as it was observed in U251 glioma cells (Griguer et al.,
2008).
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Table 1. Typical values of the biological parameters taken for our model equations
Parameter Value and units Meaning Reference Variation
C(M) 106 cell/cm2 Maximum tumor cell density Rockne et al. (2010) No
O(S)2 7 mmHg Oxygen concentration level Vaupel (2004) No
switch to hypoxia
O(T )2 2.5 mmHg Michaelis Menten threshold Dac¸u et al. (2003) No
O(D)2 0.7 mmHg Critical anoxia level Brown et al. (2004) No
Ov2 80 mmHg Typical oxygen pressure Kimura et al. (1996) No
within vessels
αn 7.5× 10−4 Typical normoxic cell Dac¸u et al. (2003) No
mmHg c/s oxygen consumption
αh αn/5 mmHg c/s Typical hypoxic cell Griguer et al. (2008) No
oxygen consumption
DO2 10−5 cm2/s Oxygen diffusion coefficient Dac¸u et al. (2003) No
τnh 0.15 h Normoxic to hypoxic Jewel et al. (2001) No
phenotype switch time
τhd 7 days Anoxic death time Martı´nez-Gonza´lez et al. (2012) No
JO2 10−6 s−1 Oxygen flow coefficient Estimated No
∆c 0.02 C(M) cells Sensitivity vascular threshold Estimated No
Dn 5× 10−10 cm2/s Normoxic and hypoxic 10%
Dh 5× 10−9 cm2/s diffusion coefficients Rockne et al. (2010) 10%
τn 14 days Normoxic and hypoxic Estimated by Fisher- 10%
τh 24 days doubling times Kolmogorov approx. 10%
τhn 96 hours Hypoxic to normoxic Semenza (2009) 10%
phenotype switch time Hsieh (2010)
C(F) 0.5 C(M) Critical cell number Ruf et al. (2010) 10%
for fluctuating hypoxia
C(C) 0.7 C(M) Critical cell number Ruf et al. (2010) 5%
for chronic hypoxia
τhn 8-48 hours Hypoxic to normoxic Semenza (2009) 5%
phenotype switch time
under AO therapy Hsieh (2010)
C(F) 0.6-0.8 C(M) Cell number thresholds Ruf et al. (2010) 5%
C(C) 0.8-0.99 C(M) for fluctuating and chronic 1%
hypoxia under AT
RTox 0.8 RT surviving fractions Joiner et al. (2009) 5%
RThyp 0.95 in normoxia and hypoxia 5%
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4.2 Computational details
Henceforth, we consider two possible scenarios: one corresponding to a biopsied but not totally/partially
resected tumor, and a second one where the tumor was either partially or totally resected. In both
scenarios we will assume that, prior to the application of radiotherapy, or antithrombotic (AT) and
antioxidative (AO) therapies, there is a mixture of normoxic cells plus smaller fractions of hypoxic cells
and a necrotic core.
In the case of resected tumors initially there will be a small infiltrative tumor remnant located around
the surgical border. In that case simulations start two weeks after surgery and all blood vessels are
assumed to work correctly, thus χC = χF = 1. Since the initial cell density is low, there is a good
oxygen supply at t = 0 and its redistribution is very fast, we can take O2(x,0) to be rougly uniform in
space.
Non-resected tumors will be considered of size ≈ 1.6 cm of diameter at diagnosis, with a necrotic
core at its center occupying ≈ 0.8 cm of diameter. Around the necrotic tissue a high tumor cell density
of about 0.6 (in units of C(M)) exists and is formed by normoxic and hypoxic cells. This hypercellular
region is related to the high-contrast ring which is frequently observed in T1 MRIs (with Gadollinium)
of GBMs. In our simulations, the width of this ring is about 4 mm. A very low density of hypoxic
cells infiltrating into the healthy tissue (brain parenchima) is also present. Only blood vessels located
within the necrotic compartment are considered to be non functional. We will also study smaller tumors
for partially resected tumors, of diameter ≈ 1 cm after surgery, where the necrotic core is in the center
occupying≈ 0.2 cm of diameter and radial tumor infiltration of size ≈ 0.4 cm formed by normoxic and
hypoxic cells. In that situation we will assume that there are no functional vessels in the center of the
tumor.
To solve Eqs. (2.1) and (2.3) numerically we have used a standard finite difference method of second
order in time and space with zero boundary conditions along the sides of the computational domain. We
have employed large integration domains and cross-checked our results for different domain sizes to
avoid spurious edge effects. All the results provided in the following sections are the outcome of sets
of ten simulations. Each simulation allows a random static variability (in the range of 1-10%) in the
parameters according to the last column in table 1. All variations are constant along time except z in Eq.
2.5a, which is related to the stochastic temporal variability of oxigen perfusion from the vessels. The
error bars shown in the figures correspond to the standard deviations of the results after the full set of
simulations corresponding to small variations of the parameters is computed.
5. Results
5.1 Tumor evolution
We have performed extensive simulations of the model equations (2.1-2.5) with different initial data and
for broad parameter ranges of biological significance. A typical result of the tumor density evolution is
shown in Fig. 3 for two times (days 72 and 168). In spite of the extensive cytoreduction assumed for
the surgery, tumor cells proliferate giving rise to a relapse. The first stages (not shown in the figure)
correspond to the proliferation of the normoxic component until a sufficiently high density occurs that
leads to vessel instability as described in Sec. 2.3. After 72 days, a number of vessels in the center of the
tumor have already collapsed developing anoxic areas as shown in the oxygen distribution (Fig. 3A).
As a result, a significant fraction of hypoxic cells start to coexist and compete with the normoxic ones
(Fig. 3B). Finally, a necrotic core of about 3 mm in size occupies the center of the tumor (Fig. 3D). Due
to the effect of the tumor on the vessel functionality and the differences in the cell uptake coefficients,
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there is a significant dispersion of oxygenation levels in regions containing high cell densities.
As the tumor progresses, the area occupied by damaged vessels and necrosis increases with time,
and oxygenation decreases due to the destruction of the functional vasculature (Fig. 3E). After 168
days the necrotic core already has a size of 8 mm (Fig. 3H). Necrotic areas are typically surrounded
by hypercellular regions generated by the migration of cells from low oxygen areas, resembling the
pseudopalisades observed in high-grade gliomas (Brat et al., 2004; Rong et al., 2006).
5.2 Targeting vaso-occlusions leads to a small reduction in tumor volume
We have first studied the effect of antithrombotic (AT) therapy improving vessel functionality as de-
scribed in Sec. 3.1. This therapy reduces invasion speed by keeping cells in their oxic and less motile
phenotype but the effect on tumor progression is small. An example is shown in Fig. 4A. Each point
represents the average of 10 simulations with mean values and static random variations (Table 1). The
error bars indicate the standard deviation of the results of those sets of simulations.
We have used different antithrombotic doses T1, T2, and T3 to delay vessel degradation by the tumor.
We suppose that there is a dosis-response effect. The threshold parameters for chronic and fluctuating
hypoxia for T3 are C(C) = 0.8C(M) and C(F) = 0.6C(M), for T2: C(C) = 0.9C(M), C(F) = 0.7C(M) and for
T1: C(C) = 0.99C(M), C(F) = 0.8C(M). It is clear from Fig. 4 that there are no significant differences
with the non-treated tumor volumes until the sixth week; this is the time were the tumor density becomes
large enough to impair the vessels. This therapy is able to delay the damage of the vessels but once the
new (higher) thresholds are reached no further gains are observed. We have verified this conclusion with
a large range of parameters obtaining very similar results. Thus, only minor gains are to be expected
from AT therapy unless it is combined with other agents.
5.3 Antioxidative therapy has the potential to improve survival substantially
The heterodimer HIF-1 has complex effects on tumor cell biology. On the one hand, the suppression
of the HIF-1α subunit activity severely compromises the ability of tumor cells to undergo anaerobic
glycolysis. This reduces the proliferation rate of hypoxic cells and promotes the apoptotic program in
cells that are deprived of both oxygen and glucose (Joiner et al., 2009). This is why many therapies have
tried to target HIF-1α , although their effectivity in brain tumors has not been proven yet. In our case we
propose antioxidative therapies as a way to normalize the cell response under oxic conditions.
We have used different antioxidant doses O3, O2 and O1, corresponding to a reduction in the nor-
malization times to τhn = 48,24, and 8 hours respectively. Our simulations encompass a time window
of six months for the tumor volume evolution with and without AO therapies. The results are depicted in
Fig. 4B. Since the AO therapy promotes the proliferative phenotype, vaso occlusion takes place earlier
than in the control case. This leads to the formation of cells actively migrating away from collapsed
vessels and the AO therapy does not decrease the tumor volume during the first 4 weeks. However,
maintenance of the therapy for longer times produces a significant benefit coming from the essential
lessening in the invasion speed. Even assuming a minor effect of the AO therapy (as would be the case
with O3) there is a significant tumor volume reduction (12%) after six months. Higher doses/effects
of antioxidants (O1 or O2), associated to smaller recovery times, result in substantial tumor volume
reductions (up to 40%) (Fig. 4 B). We have used a large range of parameters obtaining similar results
that would suggest that a prolonged AO therapy may be beneficial for a large number of patients.
5.4 Antithrombotics and antioxidants may have a synergistic effect leading to a substantial tumor
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FIG. 4. Volume of tumors treated with antithrombotics or antioxidants related to non treated tumors. A: Relative tumor
volume for different antithrombotic regimens (T3: C(C) = 0.8C(M) , C(F) = 0.6C(M) , T2: C(C) = 0.9C(M) , C(F) = 0.7C(M) , T1:
C(C) = 0.99C(M) , C(F) = 0.8C(M)). B: Relative tumor volume for different antioxidative regimens (O3: τhn = 48 hours O2:
τhn = 24 hours O1: τhn = 8 hours). Doted lines in A and B are the respective relative volumes for non-treated tumors. Error bars
display the standard deviation for the 10 simulations developed for each treatment varying the parameters as indicated in Table 1.
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the parameters as indicated in Table 1.
volume reduction
Having AT and AO together in our mathematical model, has the biological meaning that we are simul-
taneously targeting the coagulation cascade to delay the invasiveness process and the high levels of free
radicals that also have an effect on invasiveness.
Fig. 5 shows the typical outcome of our simulations. We have combined the therapies T1, T2, T3,
O1, O2 and O3, as described in Secs. 5.2 and 5.3, to get in silico several treatment modalities: T3+O3,
T2+O2 and T1+O1, besides the control C, which is the non treated tumor group. The error bars in
Fig. 5 display the standard deviation for ten simulations varying the parameters in Table 1, as described
previously.
Firstly, Fig. 5A exhibits the tumor volume evolution related to the control for the combined treat-
ments. All treatments show a visible volume reduction from the sixth week. After 24 weeks, the relative
tumor volume reduction, as compared to the control, is 0.83, 0.56 and 0.45 for T3+O3, T2+O2 and
T1+O1, respectively.
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Secondly, Fig. 5 subplots B, C and D show the tumor volumes after six months for each different
therapeutic modality. All of them result in a reduction in the final tumor volume after six months of
treatment, but in all cases the combination of AT and AO gives the best outcome. In some instances,
such as with the most effective therapies T1+O1, a synergistic effect is observed when combining both
therapies (see Fig. 5D).
5.5 Antithrombotics and antioxidants sensitize the tumor for cytotoxic therapies
An interesting result of our simulations is that the combination of antithrombotics and antioxidants re-
sults in a reduction of hypoxic areas and the normalization of cell phenotypes that results in a higher
sensitivity to cytotoxic therapies. In what follows we will discuss the action of radiotherapy (RT) to-
gether with the AT and AO therapies. As discussed in Sec. 3.3, well oxygenated cells suffer more
damage when exposed to radiation. In addition, more aggressive phenotypes, such as those induced by
hypoxia, have higher levels of repair enzymes that makes them less sensitive to cytotoxic therapies.
We have run a set of simulations combining RT with AT and AO for tumors of different initial size
at diagnosis. We display examples of their evolution, comparing different combination therapies and
initial conditions: totally resected tumors after surgery (Fig. 6), partially resected tumors (Fig. 8) and
biopsied tumors without an extensive tumor volume reduction (Fig. 7).
A first example of our results is plotted in Fig. 6 where we show the in silico predictions for the
tumor volume evolution (Fig. 6A), radial tumor velocity (Fig. 6B), for different therapeutic modalities
during a period of 58 weeks, together with the final volumes comparing all therapies Fig. 6 C. Following
the standard practice for GBM we will assume that RT starts two weeks after surgery and runs for 6
weeks from monday to friday in fractions of 2 Gy. It is clear from Fig. 6A and B that there are no
significant volume or growth speed differences between the irradiated tumors until week 12. The effect
of RT results in a substantial reduction in tumor volume and tumor growth speed that is still apparent
several months after the therapy has finished. It is also obvious that combination therapies of RT with
the different agents are always more effective than radiotherapy alone. It is remarkable that the effect of
AT+AO is equivalent, after one year, to the effect of RT, though with a much lower toxicity (and long-
term effects). At the end of the studied period of 58 weeks, there is a 12% reduction for AT alone and a
remarkable 42% decrease with AO alone. The mean final tumor volume for the combination of T1+O1
is similar to the one obtained for tumors receiving only RT; both displaying a reduction of more than
50% when compared to the control group. RT+AT gives rise to about 55% reduction, RT+AO to around
65% and the combination RT+AT+AO exhibits over 70% of tumor volume at week 58th compared to
the non-treated tumors.
Our results suggest that a substantial increase of several months in the median overall survival for
GBM patients may be obtained by combining RT+AT+AO.
5.6 Antithrombotics and antioxidants might be more effective for patients having only a biopsy or
subtotal resections
Fig. 7 displays the tumor volume evolution for the different therapeutic modalities during 24 weeks
after diagnosis. In this case, the tumor was not resected and its diameter at diagnosis was higher than
1.6 cm. Only vessels located between 20 and 30 mm were considered non functional since almost this
space was occupied by dead cells as illustrated in the initial cell density subplot Fig. 7A. Tumor volume
evolution is shown in Fig. 7B and evidences how all therapies delay tumor progression almost from the
first day, a fact that did not occur for totally resected tumors.
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FIG. 6. Tumor volume and tumor radial velocity for different therapeutic modalities. Subplots A and B display the tumor
volume (cm3) and the tumor radial velocity (cm/y) during 58 weeks, respectively. Each line provides the results for a therapeutic
modality: C is the control (non-treated), T1 (antithrombotics): C(C) = 0.99C(M) , C(F) = 0.8C(M) , O1 (antioxidants): τhn = 8 hours,
T1+O1 (antithrombotics+antioxidants), R (standard radiotherapy with 30 sessions, 2 Gy/session, monday-friday), R+T1 (ra-
diotherapy+antithrombotics), R+O1 (radiotherapy+antioxidants), R+T1+O1 (radiotherapy+antithrombotics+antioxidants). Red
curves correspond to non-radiated tumors and blue curves to radiated ones. Subplot C shows the relative final volume for all
treatments after 58 weeks. Error bars display the standard deviation for the 3 simulations developed for each treatment varying
the parameters as indicated in Table 1.
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At the end of the 24 weeks, we find a benefit in the reduction of tumor volume similar to the one
obtained from totally resected tumors after 58 weeks of treatment modalities (Fig. 7C). Thus, the group
of patients with biopsy or subtotal resection might benefit even more from a combination of AT and AO
therapies. In addition, when both AT and AO are used together with radiotherapy a significant advantage
is obtained when compared with radiotherapy alone. This gain is more evident for patients having only
a biopsy or subtotal resections, than in tumors with small remnants that are expected to be initially well
oxygenated.
5.7 Combination of antithrombotics and antioxidants might be more effective than radiotherapy alone
The last example shown in Fig. 8 displays the tumor volume evolution for the different therapeutic
modalities during the first 48 weeks after subtotal resection. In this case, the tumor diameter following
surgery was around 1 cm. Initially, the vessels in the center of the tumor were taken to be non functional
leading to the formation of a small necrotic core. Hypoxic and normoxic cells, surrounding the necrotic
areas, infiltrate into the healthy tissue Fig. 8A. The initial distribution of the partial pressure of oxygen
is displayed in Fig. 8B.
After 48 weeks all treated tumors significantly reduced their volume compared to the non treated
ones. It is remarkable that radiotherapy implies a 35% reduction versus the 55% reduction observed in
Fig. 6C for totally resected tumors. The cause of this fact can be the better initial oxygenation and the
absence of necrosis and hypoxic cells in the second case. However, antioxidants and antithrombotics
are still as effective as in Fig. 6. In addition, after 48 weeks, the benefit obtained from the combination
of AT and AO with radiotherapy is more apparent for these cases (see Fig. 8C).
Although the best result is obtained with a combination of the three proposed therapies, it is im-
portant to emphasize the fact that AO alone or AO with AT (without radiation) produced a reduction in
tumor volume larger than the one observed under radiotherapy alone (see Fig. 8D).
6. Discusion and conclusions
As a consequence of cyclic hypoxia during GBM progression, free radicals are mainly originated from
the mitochondrial respiratory chain which regulates the transcription hypoxia-inducible factor HIF-1α
expression. Indeed, hypoxia (particularly via HIF-1α) is responsible for metabolic and phenotypic
changes which induce invasiveness of GBM cells and initiate coagulation mechanisms that promote
tumor growth acceleration.
The antioxidative treatment may result in the inhibition of HIF-1α leading to a reduction of the
tumor invasiveness, delaying progression of GBM in humans. In addition, the increase of free radi-
cal could be stabilized by means of an antioxidative therapy, controlling or delaying the vascular de-
generation due to the malformations of endothelial cells induced by the HIF-1α pathway activation.
In this way, targeting HIF-1α can be seen as an attractive approach to complement radiotherapy and
chemotherapy, which kill well-oxygenated cells (Joiner et al. (2009); Chen et al. (2011)) and also to in-
activate extrinsic HIF-1α pathways, forcing the tumor to display a lower-grade behavior by reducing
invasion and angiogenesis.
Other potential interesting agents for GBM treatment are antithrombotics, such as low molecular
weight heparine (LMWH), a low molecular weight heparin that promotes the release of tissue fac-
tor pathway inhibitors for preventing venous thromboembolism and with very low toxicities (Plane`s,
2003). Thus LMWH might be incorporated as a part of GBM treatment to avoid vaso-occlusion phe-
nomena and to delay the neovascularization process associated with this pathology. The results from
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FIG. 8. Tumor volume evolution for different therapeutic modalities after subtotal resection. Subplot A shows the initial
cell density distribution for hypoxic, normoxic and necrotic cells. Initial tumor diameter ≈ 1 cm, necrotic core ≈ 0.2 cm and
radial tumor infiltration ≈ 0.4 cm. B displays the initial distribution of the partial pressure of oxygen. Vertical red lines rep-
resent the functional vessels and blue lines the oxygenation along the space. There are no functional vessels at the center of
the tumor. Subplot C shows the relative final volume for all treatments after 48 weeks. Subplot D displays the tumor volume
evolution (cm3) during 48 weeks. Each line provides the results for a therapeutic modality : C is the control (non-treated), T1
(antithrombotics): C(C) = 0.99C(M) , C(F) = 0.8C(M) , O1 (antioxidants): τhn = 8 hours, T1+O1 (antithrombotics+antioxidants), R
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blue curves to radiated ones. Error bars display the standard deviation for the 3 simulations computed for each treatment varying
the parameters as indicated in Table 1.
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our model seem to imply that an additional indirect antitumoral effect from thromboprophylaxis might
be expected related to the delay of tumor invasion, different from the direct antitumoral effect or the
increase in survival and quality of life to be expected from the prevention of the formation of big coag-
ulates. Furthermore, from our simulations shown in Fig. 4A, it follows that an optimum antithrombotic
treatment regimen exists (in our case, T2: C(C) = 0.9C(M), C(F) = 0.7C(M) in comparison with T3 or
T1) as evidenced by a U-effect on the relative tumor volume.
In addition, antithrombotic therapy could avoid early tumor-induced vaso occlusions delaying the
so-called malignant transformation of low-grade gliomas, were they transition to a high-grade glioma.
Consequently, antithrombotic therapy administered to WHO grade II astrocytic and oligodendroglial
patients may help to preclude the malignant transformation into secondary GBM associated with the
onset of hypoxia once local vascular damage is produced.
Finally, Targeting HIF-1α and vasculature normalization simultaneously in GBM may have a syn-
ergistic effect decreasing tumor invasion and increasing patient overall survival time by changing the
tumor microenvironmental behavior from high grade to low grade glioma. In addition, tumor cells have
high levels of antioxidative enzymes which contribute to eliminate more efficiently the free radicals
produced by alkylating agents such as carmustine (BCNU) or by the radiation. Besides the radiotherapy
sensitization obtained with a better tumor oxygenation, the treatment would also reduce the need to
activate antioxidative enzymes, rendering the tumor more susceptible to the effect of these agents. Fig.
1 summarizes the possible synergetic effect predicted by our in silico model combining antioxidants,
antithrombotics and radiotheraphy in the GBM treatment.
It is worth to mention the use of anti-angiogenics in the context of the go or grow hypothesis. On
the one hand, anti-angiogenic treatments impair tissue oxygenation and promote motile phenotypes to
dominate the tumor population and invade faster the adjacent tissue. On the other hand, a pro-vascular
therapy may oxygenate the tumor with the risk of producing leaky vessels through which tumor cells
can intravasate and form distant foci in the brain parenchyma. This has lead to a long discussion on the
potential existence of a window where anti-angiogenic therapies may be useful mainly as a concomitant
one. It would be very interesting to develop mathematical models of these phenomena in order to guide
the use of these therapies, specially after the recent results clinical trials investigating the combination
of antiangiogenic therapies with the standard of care that have shown no impact on overall survival
(Herriksson et al., 2013; Wick et al., 2013), though the progression free survival seems to benefit from
the use of these drugs.
It is important to remark that stochastic fluctuations in the therapy might affect the tumor dynam-
ics. These changes can be due to stochastic variations of the drug pharmaco-kinetics as shown by
(d’Onofrio and Gandolfi, 2010). However, in this paper we have assumed that drug administration is
such that the drugs achieve their therapeutical regimes that is preserved during treatment and constant
in each simulation.
Other results from our simulations are that the different treatment modalities proposed suggest a
more substantial effect on larger initial tumors that on smaller ones. Thus, the combination of an-
tithrombotics and antioxidants might be more effective for patients having only a biopsy or subtotal
resections than for those in which the tumor could be macroscopically resected. In fact, for non resected
tumors, a combination of antithrombotics and antioxidants could be more effective than radiotherapy
alone probably due to the poor oxygenation and the presence of necrosic and hypoxic areas within the
tumor. In addition, this combined therapy could even be more favorable for those patients with high risk
of vessel coagulation.
In conclusion, we have developed a biocomputational model of glioblastoma multiforme that incor-
porates the spatio-temporal interplay among two glioma cell phenotypes corresponding to oxygenated
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and hypoxic cells, a necrotic core and the local vasculature whose response evolves with the tumor
progression. Our in silico approach reveals that the different therapeutic modalities which combine
antithrombotics and antioxidants would improve vessel functionality, avoiding vaso-occlusions and re-
ducing oxidative stress and the subsequent hypoxic response. This combined treatment would reduce
glioma cell invasion and sensitize glioblastoma to conventional radiotherapy, hopefully increasing pa-
tients survival.
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